Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Dose Escalation and Cohort Expansion Study Evaluating MCLA-158 (Petosemtamab) as Single Agent or in Combination in Advanced Solid Tumors

NCT03526835 is registered in ClinicalTrials.gov with Merus B.V. as lead sponsor.

NCT NCT03526835
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03526835 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Dose Escalation and Cohort Expansion Study Evaluating MCLA-158 (Petosemtamab) as Single Agent or in Combination in Advanced Solid Tumors
Lead sponsor
Merus B.V.
Phase
Phase 1/2
Overall status
Recruiting
Start date
May 2, 2018
Completion date
November 30, 2028
Enrollment
560 (estimated)
Sites
54

Conditions

As the registry lists them; a condition with its own page is linked.

advanced/metastatic solid tumors, colorectal cancer, esophageal cancer, gastric cancer, gastroesophageal-junction cancer, head and neck squamous cell carcinoma, hnscc, nsclc